Retrospective analysis of routine use of a double heat cycle (DHC) during radiofrequency segmental ablation (ClosureFAST™) of saphenous veins

Background Recent experimental evidence suggests that increasing energy delivered during radiofrequency segmental ablation (RFSA) of varicose veins might further improve outcomes. Objectives To evaluate occlusion rates and safety of the routine use of double heat cycle (DHC) during RFSA of incompete...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the European Academy of Dermatology and Venereology 2016-06, Vol.30 (6), p.1009-1012
Hauptverfasser: Schuller-Petrović, S., Pavlović, M.D., Schuller-Lukić, B., Schuller, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Recent experimental evidence suggests that increasing energy delivered during radiofrequency segmental ablation (RFSA) of varicose veins might further improve outcomes. Objectives To evaluate occlusion rates and safety of the routine use of double heat cycle (DHC) during RFSA of incompetent saphenous veins up to 3 years after the initial treatment. Methods Retrospective review of prospectively collected duplex ultrasound (DUS) and complication rate data of successive patients from the Viennese, Lower Austrian and Slovenian regions treated for incompetent saphenous veins, followed up on a yearly basis for up to 3 years after the procedure. Results Between 2007 and 2011, 258 patients (389 veins; 322 great saphenous veins (GSV)] had been treated with DHC ClosureFast. Patients’ return was 46% (122 subjects) 3 years after RFSA [140 GSV and 31 small saphenous veins (SSV)] with a mean follow‐up time of 24.93 ± 11.77 months. At 36 months Kaplan–Meier survival analysis showed the occlusion probability of 98.6% (95% CI: 1.005–0.966). All SSV were closed. Except for three cases of dysaesthesia which disappeared within a year, there have not been major side‐effects. Conclusions Results of the retrospective analysis indicate that the routine use of DHC during RFSA for incompetent saphenous veins is equally safe but potentially more efficacious considering mid‐term venous closure rates.
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.13178